Tackling Coronavirus
Through Science and Collaboration

CARE

(Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. With a coalition of Europe’s best scientific minds from 37 globally-renowned research institutions and pharmaceutical companies, together with partners from the USA and China it provides a multi-disciplinary team with proven expertise and capabilities in anti-viral drug development.

WATCH THE PRESENTATION

THE CARE CONSORTIUM ADDRESSES TWO KEY GOALS

1

EMERGENCY RESPONSE

The development of therapeutics to provide an emergency response towards the current COVID-19 pandemic.

icon-7

Drug positioning / repurposing

Screening and profiling compound libraries to progress molecules to advanced stages of clinical testing within 18 months.

2

LONG TERM STRATEGY

The development of therapeutics to address the current and/or future coronavirus outbreaks.

icon-8

Small molecule drug discovery

Target-based and in silico screening and profiling of candidate compounds against SAS-CoV-2 for clinical testing in 36 months.

icon-9

Virus-neutralising antibody discovery

Fully human phage and yeast display, immunisation of humanised models, patient B cells and in silico design for clinical testing within 36 months.

KEY FIGURES

Ambition to accelerate effective therapies to COVID-19 patients in Europe and around the world, and generate a truly transformative treatment regimen.

The largest European research initiative addressing the challenges of COVID-19.

Coalition of Europe’s best scientific minds from 37 globally-renowned research institutions and pharmaceutical companies, together with partners from the USA and China.

A multi-disciplinary team with proven scientific and technical expertise and capabilities in anti-viral drug development.

75.8 million Euro investment over 5 years with a grant from the Innovative Medicines Initiative and contributions from EFPIA partners, IMI Associated Partners and other organisations.

Combines a focus on rapid emergency response with focus on long-term preparedness for future outbreaks.

CARE IN NUMBERS

icon-4

37

International Partners

icon-10

11

Countries

icon-5

36,5

M€ funding from IMI

icon-5

39,3

M€ co-funding by partners

icon-6

5

Years duration (2020-2025)